

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Forbes Medi-Tech (Research), Inc.	08/15/2008

RECEIVING PARTY DATA	
Name:	Transition Therapeutics Inc.
Street Address:	101 College Street
Internal Address:	Suite 220
City:	Toronto, Ontario
State/Country:	CANADA
Postal Code:	M5G 1L7

PROPERTY NUMBERS Total: 15

Property Type	Number
Application Number:	60617500
Application Number:	11245499
Application Number:	11279238
Application Number:	11539613
Application Number:	11869032
Application Number:	12093195
Application Number:	60617911
Application Number:	60664835
Application Number:	60664919
Application Number:	60693463
Application Number:	11248491
Application Number:	60824897
Application Number:	11851935
Application Number:	60829277

CH \$600.00 60617500

Application Number:

11871720

CORRESPONDENCE DATA

Fax Number: (215)540-5818

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 215-540-9200

Email: suchin@howsonandhowson.com

Correspondent Name: Howson & Howson LLP / Summer Uchin

Address Line 1: 501 Office Center Drive

Address Line 2: Suite 210

Address Line 4: Fort Washington, PENNSYLVANIA 19034

ATTORNEY DOCKET NUMBER:

TTH SERIES

NAME OF SUBMITTER:

Summer Uchin

Total Attachments: 6

source=TTHAssignment#page1.tif

source=TTHAssignment#page2.tif

source=TTHAssignment#page3.tif

source=TTHAssignment#page4.tif

source=TTHAssignment#page5.tif

source=TTHAssignment#page6.tif

ASSIGNMENT

WHEREAS in accordance with an Assignment Agreement effective August 15, 2008, Forbes Medi-Tech (Research), Inc. 10931 North Torrey Pines Road, Suite 105, La Jolla, California, 92037 (hereinafter "ASSIGNOR") assigned and transferred to Transition Therapeutics Inc., 101 College Street, Suite 220, Toronto, Ontario, M5G 1L7 (hereinafter "ASSIGNEE") all its right, title and interest in and to the patents and patent applications listed in Exhibit A hereto and the inventions described and claimed therein, including any and all utility applications, divisions and continuations thereof, and any and all Letters Patent which may be granted from the applications, including any and all renewals, reissues, reexaminations and extensions thereof (hereinafter "Assigned Patents");

AND WHEREAS ASSIGNOR wishes to confirm that it has assigned its entire right, title and interest in and to the Assigned Patents to ASSIGNEE.

NOW, WITNESSETH that for good and valuable consideration, the receipt whereof was and is acknowledged by ASSIGNOR, the ASSIGNOR by these presents hereby confirms that it assigned, sold and transferred to ASSIGNEE, its assigns and legal representatives, its entire and exclusive right, title and interest in and to said Assigned Patents, and in and to any and all priority and/or convention rights or benefits accruing or to accrue with respect to the filing or securing of patents in the United States and/or any countries foreign thereto, said ASSIGNEE, its assigns and legal representatives to have, hold, exercise, and enjoy said Assigned Patents, with all the rights, powers, privileges and advantages in any way arising from or appertaining thereto, including all rights, if any, to sue for past infringement, for and during the term or terms of any and all Letters Patent when granted, including any and all renewals, reissues, reexaminations and extensions thereof, for the use and benefit of ASSIGNEE and its assigns and legal representatives, in as ample and beneficial a manner to all intents and purposes as the ASSIGNOR might or could have held or enjoyed the same, if the assignment had not been made.

AND ASSIGNOR confirms that it has agreed to execute all papers that may be necessary to file applications in the United States and foreign countries for said inventions and to assign its rights to same to said ASSIGNEE, its assigns and legal representatives and to execute any other papers that may be needed in connection with filing said applications and securing Letters Patents thereon.

AND ASSIGNOR authorizes and requests the Commissioner of Patents & Trademarks to issue any Letters Patent to ASSIGNEE, its assigns and legal representatives, in accordance herewith.

IN TESTIMONY WHEREOF this confirmatory assignment is executed by the ASSIGNOR this 15th day of August, 2008.

FORBES MEDI-TECH (RESEARCH), INC.

Per:



Name: David Goold
Title: Chief Financial Officer
Date: August 15, 2008

Exhibit A
Assigned Patent Rights

Title	Country	Filing Date	Application No.	Date Issued	Patent No.
Vasoactive Intestinal Polypeptide Pharmaceuticals	United States	10/08/2004	60/617,500		
Vasoactive Intestinal Polypeptide Pharmaceuticals	United States	10/07/2005	11/245,499		
Vasoactive Intestinal Polypeptide Pharmaceuticals	United States	04/10/2006	11/279,238		
Vasoactive Intestinal Polypeptide Pharmaceuticals	United States	10/06/2006	11/539,613		
Vasoactive Intestinal Polypeptide Pharmaceuticals	United States	10/09/2007	11/869,032		
Vasoactive Intestinal Polypeptide Pharmaceuticals	WIPO	10/07/2005	PCT/US2005/036235		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Australia	10/07/2005	2005294125		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Brazil	10/07/2005	PI05161266		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Canada	10/07/2005	2,584,095		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Europe	10/07/2005	05806444.5		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Israel	10/07/2005	182342		
Vasoactive Intestinal Polypeptide Pharmaceuticals	India	10/07/2005	2608/DELNP/2007		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Japan	10/07/2005	2007-535856		
Vasoactive Intestinal Polypeptide Pharmaceuticals	China	10/07/2005	200580039056.7		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Hong Kong	10/07/2005	08103883.6		
Vasoactive Intestinal Polypeptide Pharmaceuticals	South Korea	10/07/2005	10-2007-7008327		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Mexico	10/07/2005	Mx/a/2007/00416		
Vasoactive Intestinal Polypeptide Pharmaceuticals	WIPO	10/06/2006	PCT/US2006/039267		
Vasoactive Intestinal Polypeptide Pharmaceuticals)	Canada	10/06/2006	TBD		
Vasoactive Intestinal Polypeptide Pharmaceuticals	Europe	10/06/2006	06816480.5		
Vasoactive Intestinal Polypeptide Pharmaceuticals	United States	05/08/2008	12/093,195		
Vasoactive Intestinal Polypeptide Pharmaceuticals	WIPO	10/08/2007	PCT/US2007/080738		

Title	Country	Filing Date	Application No.	Date Issued	Patent No.
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	10/12/2004	60/617,911		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	03/23/2005	60/664,835		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	03/23/2005	60/664,919		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	06/23/2005	60/693,463		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	10/12/2005	11/248,491	03/13/2007	7,189,748
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	12/29/2006	11/618,120		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	WIPO	10/12/2005	PCT/US2005/036702		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	Australia	10/12/2005	2005295080		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	Brazil	10/12/2005	PI05159920		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	Canada	10/12/2005	2,583,947		

Title	Country	Filing Date	Application No.	Date Issued	Patent No.
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	China	10/12/2005	200580039238.4		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	Europe	10/12/2005	05809923.5		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	Israel	10/12/2005	182443		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	India	10/12/2005	2662/DELNP/2007		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	Japan	10/12/2005	2007-536845		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	Mexico	10/12/2005	Mx/a/2007/004262		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	South Korea	10/12/2005	10-2007-7008297		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	09/07/2006	60/824,897		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	WIPO	09/07/2007	PCT/US2007/077884		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	09/07/2007	11/851,935		

Title	Country	Filing Date	Application No.	Date Issued	Patent No.
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	10/12/2006	60/829,277		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	WIPO	10/12/2007	PCT/US2007/081303		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy/Treating Metabolic Syndrome and Inflammation	United States	10/12/2007	11/871,720		
Compounds and Methods for Treating Insulin Resistance and Cardiomyopathy	WIPO	12/28/2007	PCT/US2007/089054		